Patient Support

Cohort study explores value-based insurance designs, while also determining how one’s place of residency can potentially play a role.

Researchers explore the proportion of approved drugs in the Canadian marketplace that utilize manufacturer-sponsored patient support programs, along with the types of medications that are more likely to do so.

And the need to boost awareness of this critical healthcare resource.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

EdenHelp is expected to provide HCPs and patients with real-time access to Rx drug and medical device information.

The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

Study examines the parallels between doctorate students and the US population.

How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

Breakout session summarizes key areas that will affect all aspects of the industry.

Bayer executive talks Enable Holistic Hub and Provider Services panel.

Session discusses ways to integrate digital pharmacies and hubs.

Founding Partner of Curatio Scientia speaks on her upcoming panel at Trade & Channel Strategies 2023.

Lexicon Pharmaceuticals exec discusses upcoming Enable Holistic Hub and Provider Services panel.

Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.

To rebuild trust, companies should utilize a customer-centric approach, focusing on transparent and neutral content incorporating medical expertise and regularly seeking HCP feedback.

Will result from Medicare reforms, despite increased drug uptake.

Methods that pharma companies can use to make the hub more personalized and experiential.

How to provide effective brand engagement in this rocky yet emerging landscape.

Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.

Study emphasizes role in bridging research and development and commercial/marketing functions.

Digital twins allow the industry to integrate sustainable practices and supply chain efficiency solutions while ensuring patient safety.

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.